Jens Nielsen
Chief Executive Officer at Bioinnovation Institute
Profile
Jens Nielsen was the founder of Fluxome Sciences A (founded in 2002), MycoTeQ A (founded in 2006), and Elypta AB (founded in 2017) where he held the title of Director.
He is currently the Chief Executive Officer at Bioinnovation Institute and a Professor at Chalmers University of Technology.
His former positions include Director at MetaboGen AB and Professor at Technical University of Denmark where he held the title of Professor from 2006 to 2007.
Dr. Nielsen received his graduate and doctorate degrees from Danmarks Farmaceutiske Universitet.
Jens Nielsen active positions
Companies | Position | Start |
---|---|---|
Chalmers University of Technology | Corporate Officer/Principal | 19/06/2009 |
Elypta AB
Elypta AB Packaged SoftwareTechnology Services Elypta AB develops the first metabolism-based liquid biopsy platform enabling early detection and closer follow-up of cancer. The company was founded by Francesco Gatto and Jens Nielsen in 2017 and is headquartered in Stockholm, Sweden. | Founder | 01/01/2017 |
Bioinnovation Institute
Bioinnovation Institute Miscellaneous Commercial ServicesCommercial Services Part of Novo Nordisk A/S, Bioinnovation Institute is a non-profit foundation based in Copenhagen, Denmark. The Danish company offers a +1000 square meters of laboratory space to entrepreneurs and researchers in life science to bring interdisciplinary ideas to life and research to market. The program combines business acceleration, scientific development, and team development to help start-ups in the early phases. The CEO of the company is Jens Nielsen. | Chief Executive Officer | - |
Former positions of Jens Nielsen
Companies | Position | End |
---|---|---|
Fluxome Sciences A/S
Fluxome Sciences A/S BiotechnologyHealth Technology Fluxome, a Copenhagen-based Danish company, is a recognized leader in the field of industrial biotechnology. Fluxome uses its proprietary, cutting-edge microbial metabolic engineering technology platform to build highly efficient cell factories for the production of a broad range of commercially important nutraceutical ingredients. Fluxome's technology allows the company to rapidly develop and commercialize high purity, natural products manufactured using cost-effective bioprocesses. | Founder | 08/08/2013 |
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Founder | 02/04/2012 |
Technical University of Denmark | Director/Board Member | 01/01/2006 |
MetaboGen AB
MetaboGen AB Internet Software/ServicesTechnology Services MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden. | Director/Board Member | - |
Training of Jens Nielsen
Danmarks Farmaceutiske Universitet | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Fluxome Sciences A/S
Fluxome Sciences A/S BiotechnologyHealth Technology Fluxome, a Copenhagen-based Danish company, is a recognized leader in the field of industrial biotechnology. Fluxome uses its proprietary, cutting-edge microbial metabolic engineering technology platform to build highly efficient cell factories for the production of a broad range of commercially important nutraceutical ingredients. Fluxome's technology allows the company to rapidly develop and commercialize high purity, natural products manufactured using cost-effective bioprocesses. | Health Technology |
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Health Technology |
MetaboGen AB
MetaboGen AB Internet Software/ServicesTechnology Services MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden. | Technology Services |
Elypta AB
Elypta AB Packaged SoftwareTechnology Services Elypta AB develops the first metabolism-based liquid biopsy platform enabling early detection and closer follow-up of cancer. The company was founded by Francesco Gatto and Jens Nielsen in 2017 and is headquartered in Stockholm, Sweden. | Technology Services |
Bioinnovation Institute
Bioinnovation Institute Miscellaneous Commercial ServicesCommercial Services Part of Novo Nordisk A/S, Bioinnovation Institute is a non-profit foundation based in Copenhagen, Denmark. The Danish company offers a +1000 square meters of laboratory space to entrepreneurs and researchers in life science to bring interdisciplinary ideas to life and research to market. The program combines business acceleration, scientific development, and team development to help start-ups in the early phases. The CEO of the company is Jens Nielsen. | Commercial Services |
- Stock Market
- Insiders
- Jens Nielsen